Lilly launches Lormalzi for treatment of early symptomatic Alzheimer’s Disease in India
Eli Lilly and Company (India) announced the launch of Lormalzi (donanemab, 350 mg/20 mL IV vial) in India, following marketing…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lilly
Lilly’s Donanemab receives CDSCO approval for treatment of Alzheimer’s disease
Eli Lilly and Company (India) announced that the Central Drugs Standard Control Organization (CDSCO) has granted…
Lilly to build $6.5 billion API manufacturing facility in Texas
Eli Lilly and Company has announced its plan to build a new $6.5 billion manufacturing facility at Generation Park in Houston,…
Top 20 global biopharma firms see 1.7 per cent market cap growth to $3.7 billion in 2024 amid policy…
The industry’s outlook remains uncertain as it navigates complex economic and political dynamics, reveals GlobalData
Top 20 global biopharma companies report 4.3% growth in market capitalisation in Q2 2024, reveals…
Biopharma sector sees market capitalisation rise to $4 trillion, driven by strong performances from Lilly, Novo Nordisk, and…
Top 20 global biopharma companies report 2.3 per cent market cap growth in Q2 2023: GlobalData
Market cap surged from $3.49 trillion during the first quarter (Q1) of 2023 to $3.56 trillion in Q2 2023
US FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
The US Food and Drug Administration's boxed warnings on the labels of Rinvoq , Xeljanz and Olumiant flags the risk of…
CII and Lilly release white paper on diabetes care at NCD Summit
The white paper drafted with support from Population Services International is based on the recommendations that emerged from…